A source of information and resource for small investors - "Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label cell therapy. Show all posts
Showing posts with label cell therapy. Show all posts

Saturday, June 22, 2024

Agenus Inc. (formerly known as Agenus Therapeutics) is not claiming to be close to a cure for any form of cancer, but they are making significant strides in developing innovative cancer therapies.

 

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi




Agenus is focused on immuno-oncology, to leverage the immune system to fight cancer. 

Here are some of their notable developments:

  1. Checkpoint Inhibitors: Agenus has been working on various checkpoint inhibitors, which are drugs designed to block proteins that prevent the immune system from attacking cancer cells. Their pipeline includes anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, which are well-known targets in cancer immunotherapy.

  2. Next-Generation Bispecific Antibodies: These are engineered to bind to two different targets simultaneously. This approach can help direct immune cells more effectively to cancer cells.

  3. Cell Therapy: Agenus has been exploring the potential of cell therapy, particularly with their iNKT cell therapy platform. This involves using engineered invariant natural killer T cells to target and destroy cancer cells.

  4. Neoantigen Vaccines: Agenus has been developing personalized cancer vaccines that target neoantigens, which are unique mutations found in an individual's tumor. This personalized approach aims to enhance the immune response against cancer cells.

  5. Combinations and Partnerships: Agenus is also known for combining their therapies with those of other companies, either through collaborations or licensing agreements. These combinations are designed to improve the efficacy of existing treatments and explore new therapeutic avenues.

While these advancements are promising and show potential in treating various forms of cancer, it is important to note that a "cure" for cancer is a complex and multifaceted goal. Cancer is a group of diseases with diverse characteristics, and what might work for one type of cancer or patient may not work for another. Thus, the focus remains on developing effective treatments that can extend survival and improve quality of life for cancer patients.

The progress of Agenus in clinical trials and their collaborations with other companies in the biotech and pharmaceutical industry are steps towards potentially transformative cancer treatments. However, claiming a cure would be premature without further extensive clinical validation and regulatory approval.

Agenus Inc. has formed several strategic partnerships with various pharmaceutical and biotechnology companies to advance its immuno-oncology pipeline. These collaborations aim to leverage the strengths of each partner to develop and commercialize innovative cancer therapies. Here are some notable partnerships:

  1. Gilead Sciences:

    • In December 2018, Agenus entered into a partnership with Gilead Sciences. Gilead received worldwide exclusive rights to Agenus' bispecific antibody program and access to its proprietary cancer immunotherapy platform. The deal included an upfront payment, potential milestone payments, and royalties on future sales.
  2. Incyte Corporation:

    • Agenus has multiple collaborations with Incyte Corporation. The first, established in 2015, involved the development and commercialization of checkpoint inhibitors targeting GITR, OX40, and TIM-3. In 2017, they expanded their partnership to include an exclusive global license for an undisclosed novel target and additional collaborative work on undisclosed novel antibody candidates.
  3. Merck & Co. (MSD):

    • Agenus has collaborated with Merck to evaluate the combination of Agenus' QS-21 Stimulon adjuvant with Merck's vaccines. QS-21 Stimulon is an adjuvant used to enhance the body's immune response to vaccines.
  4. Betta Pharmaceuticals:

    • In 2020, Agenus partnered with Betta Pharmaceuticals to develop and commercialize balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody) in Greater China. This partnership aims to expand the clinical and commercial reach of these immuno-oncology assets.
  5. UroGen Pharma:

    • Agenus and UroGen Pharma collaborated to explore the potential use of Agenus' anti-CTLA-4 antibody zalifrelimab in combination with UroGen's RTGel™ delivery platform for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
  6. Boehringer Ingelheim:

    • In 2021, Agenus entered into a partnership with Boehringer Ingelheim to research and develop novel bispecific antibodies in the field of immuno-oncology. The collaboration includes upfront payments, milestones, and royalties on future sales.

These partnerships highlight Agenus' strategy to collaborate with leading companies to enhance the development and potential commercialization of its immuno-oncology therapies.

Through these collaborations, Agenus aims to accelerate the development of innovative treatments and expand its global reach in the oncology market.

Promising cancer treatments in it's pipeline coupled with a healthy financial book and future royalties positions Xencor for success!

The Human body is highly "Adaptive" in fighting disease, and these two companies are developing technology right now to help that system fight Cancer!


Friday, May 10, 2024

Can two small caps become the kings of synthetic biology? Only time will tell!

 Both Twist Biosciences and Ginkgo Bioworks are prominent players 

in the field of  Synthetic biology, but they have different focuses and strengths.

Let’s take a closer look at each company: Twist Biosciences: Core Focus: Twist Biosciences specializes in high-quality synthetic DNA production using its Silicon Platform. They offer custom DNA synthesis services to researchers, biotech companies, and other organizations. Technology: Their Silicon Based DNA synthesis platform allows for efficient and precise DNA manufacturing. Applications: Twist’s DNA products are used in various applications, including Gene Editing, vaccine development, Drug discovery, and more. Collaboration with Ginkgo: Twist has a collaboration with Ginkgo Bioworks, which includes a four-year supply agreement. Ginkgo purchases products from Twist, allowing them to test proteins and develop diverse solutions across multiple industries. Recent Deal: In 2022, Twist agreed to supply at least 100 million base pairs of synthetic DNA to Ginkgo over a one-year period for engineering prototype organisms. Ginkgo Bioworks: Core Focus: Ginkgo is a horizontal platform for cell programming. They aim to make programming cells as easy as programming computers. Technology: Ginkgo’s platform enables biotechnology applications across various markets, including food, agriculture, industrial chemicals, and pharmaceuticals. Applications: Ginkgo focuses on organism design and engineering, optimization, and other synthetic biology services. Collaboration with Twist: Ginkgo collaborates with Twist to secure high volumes of DNA. They have ordered approximately one billion base pairs of synthetic DNA from Twist over the past four years for various programs. Expansion Plans: Ginkgo’s collaboration with Twist aims to fuel their expansion plans in the synthetic biology field. In summary, both companies contribute significantly to the synthetic biology ecosystem, but their expertise lies in different areas.
Twist excels in DNA synthesis, while Ginkgo focuses on cell programming and organism engineering.
The collaboration between these two organizations demonstrates their commitment to advancing the field of synthetic biology.

Foot notes:

Most recently Googles "Deep Mind" Ai has been used in combination with Synbio, cell programming and gene editing, to further the advancement in cooperation with a number of companies.

With the deep, data set of Alphabet, combined with Deep Mind's cutting edge Ai, and the massive data bank that is the human DNA, medicine and medical disciplines will benefit immensely from what is coming! And, so will human kind!